This week in therapeutics




Licensing status

Publication and contact information


Pancreatic cancer

Not applicable

Mouse studies suggest radionuclide-labeled Listeria monocytogenes could help treat metastatic pancreatic cancer. In a mouse model for metastatic pancreatic cancer, an attenuated strain of L. monocytogenes showed greater infection and replication in metastatic lesions than in primary tumors and normal tissues. In the mouse model, attenuated L. monocytogenes linked to rhenium-188 (188Re) decreased the number and size of metastatic lesions compared with the bacterium or 188Re alone. Next steps include testing the 188Re-labeled L. monocytogenes in xenograft models for pancreatic cancer.
Advaxis Inc.'s Lovaxin C (ADXS11-001), a live
L. monocytogenes-based immunotherapy expressing HPV type 16 E7, is in Phase II testing to treat cervical cancer and Phase I/II testing to treat colorectal and head and neck cancers.
Aduro BioTech Inc.'s CRS-207 (ANZ-207), a live, attenuated strain of L. monocytogenes that expresses human mesothelin, is in Phase II testing to treat pancreatic cancer and Phase I testing to treat mesothelioma. (See Add radioactivity to the Listeria, page 6).

SciBX 6(17); doi:10.1038/scibx.2013.413
Published online May 2, 2013

Patented by the Albert Einstein College of Medicine of Yeshiva University; available for licensing

Quispe-Tintaya, W. et al.
Proc. Natl. Acad. Sci. USA
published online April 22, 2013;
Contact: Claudia Gravekamp,
Albert Einstein College of Medicine of Yeshiva University, Bronx, N.Y.
Contact: Ekaterina Dadachova,
same affiliation as above